Baillie Gifford & Co. cut its position in Cellectis S.A. (NASDAQ:CLLS - Free Report) by 58.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 290,429 shares of the biotechnology company's stock after selling 403,510 shares during the period. Baillie Gifford & Co. owned about 0.52% of Cellectis worth $523,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Cellectis Price Performance
Shares of CLLS stock traded down $0.01 during trading hours on Friday, hitting $1.53. The stock had a trading volume of 76,715 shares, compared to its average volume of 179,383. The stock's 50-day moving average price is $1.63 and its two-hundred day moving average price is $1.91. Cellectis S.A. has a one year low of $1.41 and a one year high of $3.38. The stock has a market capitalization of $85.04 million, a price-to-earnings ratio of -1.18 and a beta of 3.06. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78.
Wall Street Analysts Forecast Growth
CLLS has been the topic of a number of research analyst reports. Barclays lowered their price target on Cellectis from $7.00 to $5.00 and set an "overweight" rating on the stock in a report on Tuesday, November 5th. StockNews.com assumed coverage on shares of Cellectis in a research report on Wednesday. They set a "buy" rating on the stock.
View Our Latest Analysis on CLLS
Cellectis Company Profile
(
Free Report)
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Read More
Before you consider Cellectis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list.
While Cellectis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
